⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for thyroid cancer, papillary

Every month we try and update this database with for thyroid cancer, papillary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid CarcinomaNCT02418390
Thyroid Cancer,...
prophylactic ce...
20 Years - 70 YearsSeoul National University Hospital
Circulating Biomarkers to Identify Thyroid CancerNCT04594720
Thyroid Cancer
Thyroid Cancer,...
Benign Thyroid ...
Identification ...
Validation grou...
20 Years - 100 YearsChang Gung Memorial Hospital
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.NCT05247476
Thyroid Cancer,...
Hypothyroidism
L-T4
L-T4+T3 (thyroi...
18 Years - 70 YearsZhongshan Hospital Xiamen University
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid CancerNCT06068101
Thyroid Cancer,...
Primary Aldoste...
Secreening test...
18 Years - Instituto do Cancer do Estado de São Paulo
The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid CarcinomaNCT02418390
Thyroid Cancer,...
prophylactic ce...
20 Years - 70 YearsSeoul National University Hospital
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid CancerNCT06068101
Thyroid Cancer,...
Primary Aldoste...
Secreening test...
18 Years - Instituto do Cancer do Estado de São Paulo
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315
Neoplasms
Colorectal Neop...
Melanoma
Pancreatic Neop...
Sarcoma
Ovarian Neoplas...
Brain Neoplasms
Thyroid Neoplas...
Neuroendocrine ...
Cholangiocarcin...
Salivary Gland ...
Head and Neck N...
Thyroid Cancer,...
Lymphoma, Large...
Neoplasms by Si...
Respiratory Tra...
Thoracic Neopla...
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
Central Nervous...
Alectinib
18 Years - Hoffmann-La Roche
Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective CohortNCT04396912
Iatrogenic Hypo...
Iatrogenic Hypo...
Vocal Cord Para...
Vocal Cord Pare...
Vocal Cord; Inj...
Thyroid Cancer,...
Thyroid Cancer
Multinodular Go...
Thyroid Neoplas...
Thyroid Nodule
Calcium Deficie...
PTH
Total thyroidec...
17 Years - Umraniye Education and Research Hospital
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385
RET-altered Non...
Medullary Thyro...
RET-altered Pap...
RET-altered Col...
RET-altered Sol...
Lung Neoplasm
Carcinoma, Non-...
Thyroid Disease...
Thyroid Neoplas...
Thyroid Cancer,...
Carcinoma, Neur...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Endocrine Syste...
Endocrine Gland...
Head and Neck N...
Adenocarcinoma,...
Adenocarcinoma
Carcinoma
Neoplasms, Glan...
Neoplasms by Hi...
Neuroendocrine ...
Neuroectodermal...
Neoplasms, Germ...
Neoplasms, Nerv...
Colonic Neoplas...
Colorectal Neop...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
pralsetinib (BL...
18 Years - Hoffmann-La Roche
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.NCT05768178
Solid Tumor
Haematological ...
Melanoma
Thyroid Cancer,...
Ovarian Neoplas...
Colorectal Neop...
Laryngeal Neopl...
Carcinoma, Non-...
Glioma
Multiple Myelom...
Erdheim-Chester...
Thyroid Carcino...
Vemurafenib
Cobimetinib
18 Years - Cancer Research UK
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315
Neoplasms
Colorectal Neop...
Melanoma
Pancreatic Neop...
Sarcoma
Ovarian Neoplas...
Brain Neoplasms
Thyroid Neoplas...
Neuroendocrine ...
Cholangiocarcin...
Salivary Gland ...
Head and Neck N...
Thyroid Cancer,...
Lymphoma, Large...
Neoplasms by Si...
Respiratory Tra...
Thoracic Neopla...
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
Central Nervous...
Alectinib
18 Years - Hoffmann-La Roche
Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid SurgeryNCT06254859
Thyroid Cancer
Thyroid Cancer,...
Traditional thy...
- Fujian Medical University
European Multicenter Study on Surgical Management of Advanced Thyroid CancerNCT05796960
Thyroid Carcino...
Thyroid Cancer
Thyroid Neoplas...
Thyroid Cancer,...
Thyroid Cancer,...
Thyroid Medulla...
Anaplastic Thyr...
Thyroidectomy w...
18 Years - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Leptin Levels in Papillary Thyroid CancerNCT01659385
Thyroid Cancer,...
Leptin Levels
19 Years - 75 YearsUniversity of Nebraska
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388
Differentiated ...
Cabozantinib
Placebo
16 Years - Exelixis
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is EvaluatedNCT06439745
Papillary Thyro...
Papillary Carci...
Thyroid Cancer
Thyroid Carcino...
Thyroid Cancer,...
Lymph Node Meta...
18 Years - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: